10-Q: Varex Imaging Reports Q2 Results: Revenue Up, Net Loss Widens

Varex Imaging Corporation's Q2 filing shows a 1.5% revenue increase to $216.0 million, but a net loss of $8.1 million compared to a profit in the prior year.

Summary

• Varex Imaging Corporation reported revenues of $216.0 million for the three months ended April 3, 2026, an increase of 1.5% from $212.9 million in the same period last year.
• The company experienced a net loss of $8.1 million for the quarter, a significant shift from a net income of $6.9 million in the prior year's comparable quarter.
• For the six months ended April 3, 2026, revenues increased by 3.1% to $425.6 million, while the net loss widened to $5.8 million from a net income of $6.6 million in the prior year.
• Gross profit for the quarter decreased by 5.3% to $72.6 million, with the Medical segment seeing a 9.5% decline in gross profit.
• Operating expenses increased by 6.6% to $58.2 million for the quarter, driven by a 10.4% rise in selling, general, and administrative expenses.
• Interest and other expense, net, significantly increased to $20.8 million from $11.3 million in the prior year's quarter, largely due to debt extinguishment costs.
• The company completed a debt refinancing, entering into a new $490 million credit facility and using proceeds to redeem $368 million of Senior Secured Notes.
• Cash and cash equivalents decreased to $85.3 million as of April 3, 2026, from $145.0 million at the end of the previous fiscal year.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the shift from profitability to a net loss, despite a slight increase in revenue, and the significant rise in operating and interest expenses.

Positives

• Total revenues increased by 1.5% to $216.0 million for the three months ended April 3, 2026, compared to $212.9 million in the prior year.
• Americas revenue saw a significant increase of 13.4% to $78.7 million for the quarter.
• Industrial segment gross profit increased by 5.8% to $22.0 million for the quarter.
• The company completed a debt refinancing, which is expected to reduce annual interest expense by more than $7 million and lower total outstanding debt.
• The new credit facility provides improved financial flexibility and supports continued investment in the business.
• Research and development expenses remained stable as a percentage of revenue at 10.3%, indicating continued investment in innovation.

Negatives

• The company reported a net loss of $8.1 million for the three months ended April 3, 2026, compared to a net income of $6.9 million in the prior year.
• Gross profit for the quarter decreased by 5.3% to $72.6 million, primarily due to a 9.5% decrease in the Medical segment's gross profit.
• Selling, general, and administrative expenses increased by 10.4% to $36.0 million for the quarter.
• Interest and other expense, net, more than doubled to $20.8 million from $11.3 million, largely due to $9.4 million in debt extinguishment costs.
• Cash and cash equivalents decreased by $59.7 million to $85.3 million.
• The company recorded a $9.2 million loss related to the redemption premium and write-off of debt issuance costs for the Senior Secured Notes.

Risks

• Changes in import/export regulatory regimes, tariffs, trade wars, and national policies continue to impact results and profitability.
• A reduction in or loss of business from one or more key OEM customers could materially reduce sales.
• Challenges in accurately predicting product demand and delivery schedules due to customer forecast changes and economic uncertainties.
• Intense competition and pricing pressures may lead to margin erosion and loss of customers.
• Global economic instability, shifting political environments, and international trade risks associated with international manufacturing, operations, and sales.
• The financial results of equity method investments, including joint ventures that are not controlled by Varex.
• Inflation and supply chain disruptions can lead to increased costs and delayed product delivery.
• Disruption of critical information systems or material breaches in the security of Varex's systems or those of third parties.
• Inability to maintain or defend intellectual property rights and the high costs associated with protecting intellectual property and defending against infringement claims.
• Noncompliance with regulations applicable to marketing, manufacturing, labeling, and distributing products, and delays in obtaining regulatory clearances or approvals.
• Limitations imposed by operating and financial restrictions of debt financing.
• The company is subject to ongoing legal proceedings and disputes, including those related to joint ventures and intellectual property matters, which could be costly and divert management attention.
• Product defects or misuse could result in material product liability claims, litigation, or recalls.
• The company's operations are vulnerable to interruption from natural disasters, climate-related events, power loss, strikes, and other events beyond its control.
• The company's dependence on a limited number of suppliers for certain components could lead to supply disruptions.
• The company's credit facility imposes significant operating and financial restrictions that may limit its flexibility.
• The company's variable rate borrowings subject it to interest rate risk.

Future Outlook

The company believes its operating cash flow, cash on hand, availability under its Revolving Credit Facility, and access to credit and capital markets are sufficient to meet its anticipated operating activities and cash commitments for at least the next 12 months, allowing for continued investment in existing businesses, strategic acquisitions, and capital structure management. The company is not aware of any trends or demands that would result in a material change to its liquidity needs in the next 12 months.

Management Comments

• We expect the refinancing to reduce annual interest expense by more than $7 million, lower total outstanding debt, improve financial flexibility, and support continued investment in the business.
• The broader trade environment remains uncertain. Tariffs, trade restrictions, retaliatory actions, and related uncertainty have contributed to, and may continue to contribute to, delayed customer purchasing decisions, increased costs, supply chain and logistics disruption, exchange rate volatility, increased shipping and transportation costs, and disputes with customers regarding potential IEEPA tariff refunds.
• We continue to monitor tariff-related actions, investigations, and policy developments, as well as changes in customer procurement decisions resulting from the current trade environment.
• We continue to work to improve the life and quality of our imaging components and leverage our scale as one of the largest independent X-ray imaging component suppliers to provide cost-effective solutions for our customers.

Industry Context

StockSavvy.ai notes that Varex Imaging's performance reflects broader industry trends in medical and industrial imaging, including ongoing impacts from global trade policies and supply chain dynamics. The company's focus on innovation in X-ray components and detectors positions it within a competitive landscape where technological advancement and cost-efficiency are key differentiators.

Comparison to Industry Standards

• The company's R&D spending as a percentage of revenue (10.3%) is within the stated target range of 8% to 10%, aligning with industry practices for companies focused on innovation in specialized technology sectors.
• The Medical segment's gross margin of 32.4% for the quarter is lower than the prior year's 36.3%, indicating potential pressure from material costs or competitive pricing within the medical imaging component market.
• The Industrial segment's gross margin of 36.8% for the quarter is higher than the prior year's 35.2%, suggesting better cost management or favorable product mix in this segment compared to Medical.
• The overall gross margin of 33.6% for the quarter is below the industry average for specialized component manufacturers, reflecting challenges in cost management and pricing power.

Legal Proceedings

• The company is subject to various claims, complaints, and legal actions in the normal course of business, but does not believe any current or pending litigation could have a material adverse effect on its operations or financial position.
• Ongoing disputes with a joint venture partner in Saudi Arabia could divert management's attention, increase costs, and adversely impact business operations.
• Judicial proceedings in Germany related to joint venture shareholder resolutions and actions concerning intellectual property, breach of contracts, and business damaging statements.

Related Party Transactions

• The company has a 40% ownership interest in dpiX Holding Company LLC, a supplier of amorphous silicon-based thin film transistor arrays. Purchases from dpiX totaled $11.3 million for the six months ended April 3, 2026. The company has fixed cost commitments of $10.2 million for calendar year 2026 related to an amended agreement with dpiX.
• The company has a 50% interest in VEC Imaging GmbH & Co. KG, a joint venture formed to develop technology for X-ray imaging components. The company recorded no income from this investment for the periods presented.
• The company has a 75% interest in Varex Imaging Arabia LLC, a joint venture in Saudi Arabia, and is experiencing ongoing disputes with its joint venture partner.

Stakeholder Impact

• Shareholders: The net loss and increased expenses may negatively impact shareholder value and confidence.
• Employees: Continued investment in R&D and potential for strategic acquisitions could lead to growth opportunities, but cost pressures and operational challenges may impact job security.
• Customers: Increased costs due to tariffs and supply chain issues may lead to price adjustments or impact product availability. The company's focus on integrated hardware and software aims to maintain customer loyalty.
• Suppliers: The company's efforts to manage supply chain disruptions and potential localization of manufacturing could impact supplier relationships.
• Creditors: The recent debt refinancing and new credit facility provide improved financial flexibility, but the company remains subject to covenants and restrictions.

Next Steps

• Continue to monitor tariff-related actions, investigations, and policy developments.
• Evaluate developments related to potential refunds of tariffs previously paid on imported goods.
• Continue to take actions intended to reduce the impact of tariffs and trade-related uncertainty, including working with customers and evaluating operational, supply chain, and pricing measures.
• Continue to invest in research and development to support long-term growth and innovation.

Key Dates

Recommendation

While revenue shows modest growth and a significant debt refinancing has improved financial flexibility, the shift to a net loss, increased operating expenses, and ongoing risks related to tariffs and supply chains warrant a cautious approach. The company's ability to navigate these challenges and return to profitability will be key factors for future performance.

Keywords

Varex Imaging, 10-Q, Quarterly Report, Medical Imaging, X-ray Components, Revenue, Net Loss, Debt Refinancing, Industrial Products, Financial Statements